Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aker ASA
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Wellness Industry Executive Decisions: AHPA's McGuffin Notes 20 Years, Aker Promotes McNeil To Innovation VP, More
AHPA's Michael McGuffin notes accomplishments in 20 years he's led trade group; CbdMD signs former NFL players as brand reps; former British Columbia trade official consults with Naturally Splendid; Canadian cannabis firm Emerald Heath appoints CEO, CCO; and Aker Biomarine promotes McNeil to innovation VP.
Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
Deals Shaping The Medical Industry, March 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
- Other Names / Subsidiaries
- Aker BioMarine ASA
- Epax Holding AS
- Trygg Pharma AS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.